Mind-body medicine in chronic heart failure: A translational science challenge

Circulation: Heart Failure

Volumn 3, Issue 6, 2010, Pages 715-725

  Emani, Sitaramesh ^a   Binkley, Philip F ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Autonomic function; Autonomic nervous system; Inflammation; Sympathetic nervous system; Vagus nerve

Indexed keywords

ARTICLE; AUTONOMIC NERVOUS SYSTEM; CONGESTIVE HEART FAILURE; EMOTION; ENVIRONMENTAL FACTOR; FEEDBACK SYSTEM; FUNCTIONAL ANATOMY; HEART FAILURE; HEART STRESS; HUMAN; INFLAMMATION; MEDITATION; NERVOUS SYSTEM; NEUROIMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; RELAXATION TRAINING; THERAPY EFFECT;

AUTONOMIC NERVOUS SYSTEM; BIOFEEDBACK, PSYCHOLOGY; CHRONIC DISEASE; EMOTIONS; HEART FAILURE; HUMANS; INFLAMMATION; MEDITATION; MIND-BODY THERAPIES; NEURAL PATHWAYS; NEUROIMMUNOMODULATION; RELAXATION THERAPY; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 78650095266     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.110.951509     Document Type: Article

References (145)

1. Chan CL, Ng SM, Ho RT, Chow AY. East meets West: applying eastern spirituality in clinical practice. J Clin Nurs. 2006;15:822-832.
2. Honderich T, editor. The Oxford Companion to Philosophy. Oxford: Oxford University Press; 1995:1009.
3. Berntson GG, Norman GJ, Hawkley LC, Cacioppo JT. Spirituality and autonomic cardiac control. Ann Behav Med. 2008;35:198-208.
4. Penn MS, Bakken EE. Heart-brain medicine: where we go from here and why. Cleve Clin J Med. 2007;74(Suppl 1):S4-S6.
5. Samuels MA. The brain-heart connection. Circulation. 2007;116:77-84.
6. Samuels MA. 'Voodoo' death revisited: the modern lessons of neurocardiology. Cleve Clin J Med. 2007;74(Suppl 1):S8-S16.
7. Cannon WB. Voodoo death. Am Anthropologist. 1942;44(new series): 169-181;
8. Am J Public Health. 2002;92:1593-1595.
9. Sgoifo A, De Boer SF, Buwalda B, Korte-Bouws G, Tuma J, Bohus B, Zaagsma J, Koolhaas JM. Vulnerability to arrhythmias during social stress in rats with different sympathovagal balance. Am J Physiol. 1998;275(2 Pt 2):H460-H466.
10. Grippo AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. Stress. 2009;12:1-21.
11. Kubzansky LD. Sick at heart: the pathophysiology of negative emotions. Cleve Clin J Med. 2007;74(Suppl 1):S67-S72.
12. Skinner JE. Role of the brain in ventricular fibrillation and hypertension: from animal models to early human studies. Cleve Clin J Med. 2007; 74(Suppl 1):S73-S78.
13. Wittstein IS. The broken heart syndrome. Cleve Clin J Med. 2007; 74(Suppl 1):S17-S22.
14. Joynt KE, Whellan DJ, O'Connor CM. Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail. 2004;10:258-271.
15. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol. 2000;35(7 Suppl 4):S1-S7.
16. Esler M, Turbott J, Schwarz R, Leonard P, Bobik A, Skews H, Jackman G. The peripheral kinetics of norepinephrine in depressive illness. Arch Gen Psychiatry. 1982;39:295-300.
17. Rechlin T, Weis M, Spitzer A, Kaschka WP. Are affective disorders associated with alterations of heart rate variability? J Affect Disord. 1994;32:271-275.
18. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol. 1995;76:562-564.
19. Krittayaphong R, Cascio WE, Light KC, Sheffield D, Golden RN, Finkel JB, Glekas G, Koch GG, Sheps DS. Heart rate variability in patients with coronary artery disease: differences in patients with higher and lower depression scores. Psychosom Med. 1997;59:231-235.
20. Watkins LL, Grossman P. Association of depressive symptoms with reduced baroreflex cardiac control in coronary artery disease. Am Heart J. 1999;137:453-457.
21. Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, Socratous F, Kaye DM, Schlaich MP, Hickie I, Lambert GW. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens. 2007;25:2117-2124.
22. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs. 2009;23:583-602.
23. Hausberg M, Hillebrand U, Kisters K. Addressing sympathetic overactivity in major depressive disorder. J Hypertens. 2007;25:2004-2005.
24. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675-1680.
25. Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol. 1991;18:464-472.
26. Eaton GM, Cody RJ, Nunziata E, Binkley PF. Early left ventricular dysfunction elicits activation of sympathetic drive and attenuation of parasympathetic tone in the paced canine model of congestive heart failure. Circulation. 1995;92:555-561.
27. Ferketich AK, Binkley PF. Psychological distress and cardiovascular disease: results from the 2002 national health interview survey. Eur Heart J. 2005;26:1923-1929.
28. Abramson J, Berger A, Krumholz HM, Vaccarino V. Depression and risk of heart failure among older persons with isolated systolic hypertension. Arch Intern Med. 2001;161:1725-1730. (Pubitemid 32679547)
29. Williams SA, Kasl SV, Heiat A, Abramson JL, Krumholz HM, Vaccarino V. Depression and risk of heart failure among the elderly: a prospective community-based study. Psychosom Med. 2002;64:6-12.
30. Cheung RT, Hachinski V. The insula and cerebrogenic sudden death. Arch Neurol. 2000;57:1685-1688.
31. Dikshit BB. The production of cardiac irregularities by excitation of the hypothalmic centres. J Physiol. 1934;81:382-394.
32. Armour JA. The little brain on the heart. Cleve Clin J Med. 2007; 74(Suppl 1):S48-S51.
33. Bennett MR, Hacker PM. Emotion and cortical-subcortical function: conceptual developments. Prog Neurobiol. 2005;75:29-52.
34. Buijs RM, Van Eden CG. The integration of stress by the hypothalamus, amygdala and prefrontal cortex: balance between the autonomic nervous system and the neuroendocrine system. Prog Brain Res. 2000;126: 117-132.
35. Furness JB. The organisation of the autonomic nervous system: Peripheral connections. Auton Neurosci. 2006;130:1-5.
36. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci. 2009;10:397-409.
37. Groenewegen HJ, Uylings HB. The prefrontal cortex and the integration of sensory, limbic and autonomic information. Prog Brain Res. 2000; 126:3-28.
38. Cheshire WP Jr, Saper CB. The insular cortex and cardiac response to stroke. Neurology. 2006;66:1296-1297.
39. Hays A, Diringer MN. Elevated troponin levels are associated with higher mortality following intracerebral hemorrhage. Neurology. 2006; 66:1330-1334.
40. Laowattana S, Zeger SL, Lima JA, Goodman SN, Wittstein IS, Oppenheimer SM. Left insular stroke is associated with adverse cardiac outcome. Neurology. 2006;66:477-483.
41. Cechetto DF, Saper CB. Role of the cerebral cortex in autonomic function. In: Loewy AD, Spyer KM, editors. Central Regulation of Autonomic Function. New York, New York: Oxford University Press; 1990:208.
42. Hoff EC, Kell JF Jr, Carroll MN Jr. Effects of cortical stimulation and lesions on cardiovascular function. Physiol Rev. 1963;43:68-114.
43. Oppenheimer S. Cortical control of the heart. Cleve Clin J Med. 2007; 74(Suppl 1):S27-S29.
44. Oppenheimer S. Cerebrogenic cardiac arrhythmias: cortical lateralization and clinical significance. Clin Auton Res. 2006;16:6-11.
45. Oppenheimer S. The anatomy and physiology of cortical mechanisms of cardiac control. Stroke. 1993;24(12 Suppl):I3-I5.
46. Oppenheimer SM, Gelb A, Girvin JP, Hachinski VC. Cardiovascular effects of human insular cortex stimulation. Neurology. 1992;42: 1727-1732.
47. Oppenheimer SM, Kedem G, Martin WM. Left-insular cortex lesions perturb cardiac autonomic tone in humans. Clin Auton Res. 1996;6: 131-140.
48. Ay H, Koroshetz WJ, Benner T, Vangel MG, Melinosky C, Arsava EM, Ayata C, Zhu M, Schwamm LH, Sorensen AG. Neuroanatomic correlates of stroke-related myocardial injury. Neurology. 2006;66: 1325-1329.
49. Allman JM, Hakeem A, Erwin JM, Nimchinsky E, Hof P. The anterior cingulate cortex. the evolution of an interface between emotion and cognition. Ann N Y Acad Sci. 2001;935:107-117.
50. Tang YY, Ma Y, Fan Y, Feng H, Wang J, Feng S, Lu Q, Hu B, Lin Y, Li J, Zhang Y, Wang Y, Zhou L, Fan M. Central and autonomic nervous system interaction is altered by short-term meditation. Proc Natl Acad Sci U S A. 2009;106:8865-8870.
51. Rapp MA, Rieckmann N, Lessman DA, Tang CY, Paulino R, Burg MM, Davidson KW. Persistent depressive symptoms after acute coronary syndrome are associated with compromised white matter integrity in the anterior cingulate: a pilot study. Psychother Psychosom. 2010;79: 149-155.
52. Besedovsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science. 1986;233:652-6524.
53. Blalock JE. Shared ligands and receptors as a molecular mechanism for communication between the immune and neuroendocrine systems. Ann N Y Acad Sci. 1994;741:292-298.
54. Blalock JE. The immune system as a sensory organ. J Immunol. 1984; 132:1067-1070.
55. Tracey KJ. The inflammatory reflex. Nature. 2002;420:853-859.
56. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.
57. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev. 1996;17:64-102.
58. Raison CL, Borisov AS, Majer M, Drake DF, Pagnoni G, Woolwine BJ, Vogt GJ, Massung B, Miller AH. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009;65:296-303.
59. Raison CL, Miller AH. The neuroimmunology of stress and depression. Semin Clin Neuropsychiatry. 2001;6:277-294.
60. Rankine EL, Hughes PM, Botham MS, Perry VH, Felton LM. Brain cytokine synthesis induced by an intraparenchymal injection of LPS is reduced in MCP-1-deficient mice prior to leucocyte recruitment. Eur J Neurosci. 2006;24:77-86.
61. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. 2008; 85:1-74.
62. Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, Kalin NH, Ratti E, Nemeroff CB, Miller AH. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry. 2007;62:1324-1333.
63. Goehler LE, Gaykema RP, Hansen MK, Anderson K, Maier SF, Watkins LR. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton Neurosci. 2000;85:49-59.
64. Goehler LE, Relton JK, Dripps D, Kiechle R, Tartaglia N, Maier SF, Watkins LR. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist: a possible mechanism for immune-to-brain communication. Brain Res Bull. 1997;43:357-364.
65. Hansen MK, Nguyen KT, Goehler LE, Gaykema RP, Fleshner M, Maier SF, Watkins LR. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-1beta protein in rats. Auton Neurosci. 2000;85: 119-126.
66. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, Ferstl R, von Eynatten M, Wendt T, Rudofsky G, Joswig M, Morcos M, Schwaninger M, McEwen B, Kirschbaum C, Nawroth PP. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A. 2003;100:1920-1925.
67. Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav Immunol. 2005;19:493-499.
68. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med. 2007;13:178-184.
69. Godbout JP, Moreau M, Lestage J, Chen J, Sparkman NL, O'Connor J, Castanon N, Kelley KW, Dantzer R, Johnson RW. Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system. Neuropsychopharmacology. 2008;33: 2341-2351.
70. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56.
71. Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. 2007;21:901-912.
72. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim CM. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163:1630-1633.
73. Capuron L, Pagnoni G, Demetrashvili M, Woolwine BJ, Nemeroff CB, Berns GS, Miller AH. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry. 2005;58:190-196.
74. Kiecolt-Glaser JK, Loving TJ, Stowell JR, Malarkey WB, Lemeshow S, Dickinson SL, Glaser R. Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry. 2005; 62:1377-1384.
75. Benedetti F, Lucca A, Brambilla F, Colombo C, Smeraldi E. Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26:1167-1170.
76. Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry. 2003;60:1009-1014.
77. Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R. Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A. 2003;100: 9090-9095.
78. Kiecolt-Glaser JK, Glaser R, Cacioppo JT, Malarkey WB. Marital stress: immunologic, neuroendocrine, and autonomic correlates. Ann N Y Acad Sci. 1998;840:656-663.
79. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103: 220-225. (Pubitemid 32095406)
80. Aukrust P, Yndestad A, Damas JK, Gullestad L. Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin. Autoimmun Rev. 2004;3:221-227.
81. Ferketich AK, Ferguson JP, Binkley PF. Depressive symptoms and inflammation among heart failure patients. Am Heart J. 2005;150: 132-136.
82. Cooke GE, Doshi A, Binkley PF. Endothelial nitric oxide synthase gene: prospects for treatment of heart disease. Pharmacogenomics. 2007;8: 1723-1734.
83. Schultz HD. Nitric oxide regulation of autonomic function in heart failure. Curr Heart Fail Rep. 2009;6:71-80.
84. Hirooka Y, Shigematsu H, Kishi T, Kimura Y, Ueta Y, Takeshita A. Reduced nitric oxide synthase in the brainstem contributes to enhanced sympathetic drive in rats with heart failure. J Cardiovasc Pharmacol. 2003;42(Suppl 1):S111-S115.
85. Wang Y, Patel KP, Cornish KG, Channon KM, Zucker IH. nNOS gene transfer to RVLM improves baroreflex function in rats with chronic heart failure. Am J Physiol Heart Circ Physiol. 2003;285:H1660-H1667.
86. Chowdhary S, Ng GA, Nuttall SL, Coote JH, Ross HF, Townend JN. Nitric oxide and cardiac parasympathetic control in human heart failure. Clin Sci (Lond). 2002;102:397-402. (Pubitemid 34275791)
87. Li YF, Roy SK, Channon KM, Zucker IH, Patel KP. Effect of in vivo gene transfer of nNOS in the PVN on renal nerve discharge in rats. Am J Physiol Heart Circ Physiol. 2002;282:H594-H601.
88. Zucker IH, Pliquett RU. Novel mechanisms of sympatho-excitation in chronic heart failure. Heart Fail Monit. 2002;3:2-7.
89. Binkley PF, Nunziatta E, Liu-Stratton Y, Cooke G. A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. Am Heart J. 2005;149:342-348.
90. Ariza ME, Glaser R, Kaumaya PT, Jones C, Williams MV. The EBVencoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J Immunol. 2009;182:851-859.
91. Waldman WJ, Williams MV Jr, Lemeshow S, Binkley P, Guttridge D, Kiecolt-Glaser JK, Knight DA, Ladner KJ, Glaser R. Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: evidence for depression-induced atherosclerotic risk. Brain Behav Immun. 2008;22: 215-223.
92. Glaser R, Litsky ML, Padgett DA, Baiocchi RA, Yang EV, Chen M, Yeh PE, Green-Church KB, Caligiuri MA, Williams MV. EBV-encoded dUTPase induces immune dysregulation: Implications for the pathophysiology of EBV-associated disease. Virology. 2006;346:205-218.
93. Padgett DA, Hotchkiss AK, Pyter LM, Nelson RJ, Yang E, Yeh PE, Litsky M, Williams M, Glaser R. Epstein-Barr virus-encoded dUTPase modulates immune function and induces sickness behavior in mice. J Med Virol. 2004;74:442-448.
94. Williams MV, Holliday J, Glaser R. Induction of a deoxyuridine triphosphate nucleotidohydrolase activity in Epstein-Barr virus-infected cells. Virology. 1985;142:326-333.
95. Melville KI, Blum B, Shister HE, Silver MD. Cardiac ischemic changes and arrhythmias induced by hypothalamic stimulation. Am J Cardiol. 1963;12:781-791.
96. Melville KI, Garvey HL, Shister HE, Knaack J. Central nervous system stimulation and cardiac ischemic changes in monkeys. Ann N Y Acad Sci. 1969;156:241-260.
97. Selye H. The chemical prevention of cardiac necrosis. New York, New York: Ronald Press; 1958.
98. Cebelin MS, Hirsch CS. Human stress cardiomyopathy. Myocardial lesions in victims of homicidal assaults without internal injuries. Hum Pathol. 1980;11:123-132.
99. Koskelo P, Punsar S, Sipilae W. Subendocardial haemorrhage and ECG changes in intracranial bleeding. BMJ. 1964;1:1479-1480.
100. Nair A, Vadodaria KC, Banerjee SB, Benekareddy M, Dias BG, Duman RS, Vaidya VA. Stressor-specific regulation of distinct brain-derived neurotrophic factor transcripts and cyclic AMP response elementbinding protein expression in the postnatal and adult rat hippocampus. Neuropsychopharmacology. 2007;32:1504-1519.
101. Vaidya VA. Stress, depression and hippocampal damage. J Biosci. 2000;25:123-124.
102. Lazar SW, Kerr CE, Wasserman RH, Gray JR, Greve DN, Treadway MT, McGarvey M, Quinn BT, Dusek JA, Benson H, Rauch SL, Moore CI, Fischl B. Meditation experience is associated with increased cortical thickness. Neuroreport. 2005;16:1893-1897.
103. Brefczynski-Lewis JA, Lutz A, Schaefer HS, Levinson DB, Davidson RJ. Neural correlates of attentional expertise in long-term meditation practitioners. Proc Natl Acad Sci U S A. 2007;104:11483-11488.
104. Barrows KA, Jacobs BP. Mind-body medicine. an introduction and review of the literature. Med Clin North Am. 2002;86:11-31.
105. Moravec CS. Biofeedback therapy in cardiovascular disease: rationale and research overview. Cleve Clin J Med. 2008;75(Suppl 2):S35-S38.
106. Moser DK, Dracup K, Woo MA, Stevenson LW. Voluntary control of vascular tone by using skin-temperature biofeedback-relaxation in patients with advanced heart failure. Altern Ther Health Med. 1997;3: 51-59.
107. Bernardi L, Porta C, Spicuzza L, Bellwon J, Spadacini G, Frey AW, Yeung LY, Sanderson JE, Pedretti R, Tramarin R. Slow breathing increases arterial baroreflex sensitivity in patients with chronic heart failure. Circulation. 2002;105:143-145.
108. Weiner P, Waizman J, Magadle R, Berar-Yanay N, Pelled B. Effect of specific inspiratory muscle training on dyspnea and exercise tolerance in congestive heart failure. Harefuah. 1999;136:774-777, 843.
109. Mangin L, Monti A, Medigue C, Macquin-Mavier I, Lopes M, Gueret P, Castaigne A, Swynghedauw B, Mansier P. Altered baroreflex gain during voluntary breathing in chronic heart failure. Eur J Heart Fail. 2001;3:189-195.
110. Swanson KS, Gevirtz RN, Brown M, Spira J, Guarneri E, Stoletniy L. The effect of biofeedback on function in patients with heart failure. Appl Psychophysiol Biofeedback. 2009;34:71-91.
111. Pace TW, Negi LT, Adame DD, Cole SP, Sivilli TI, Brown TD, Issa MJ, Raison CL. Effect of compassion meditation on neuroendocrine, innate immune and behavioral responses to psychosocial stress. Psychoneuroendocrinology. 2009;34:87-98.
112. Jayadevappa R, Johnson JC, Bloom BS, Nidich S, Desai S, Chhatre S, Raziano DB, Schneider R. Effectiveness of transcendental meditation on functional capacity and quality of life of African Americans with congestive heart failure: a randomized control study. Ethnic Dis. 2007;17: 72-77.
113. Benson H, Kotch JB, Crassweller KD. The relaxation response: a bridge between psychiatry and medicine. Med Clin North Am. 1977;61: 929-938.
114. Benson H, Greenwood MM, Klemchuk H. The relaxation response: psychophysiologic aspects and clinical applications. Int J Psychiatry Med. 1975;6:87-98.
115. Benson H, Beary JF, Carol MP. The relaxation response. Psychiatry. 1974;37:37-46.
116. Walton KG, Schneider RH, Nidich S. Review of controlled research on the transcendental meditation program and cardiovascular disease. Risk factors, morbidity, and mortality. Cardiol Rev. 2004;12:262-266.
117. Barnes VA, Treiber FA, Turner JR, Davis H, Strong WB. Acute effects of transcendental meditation on hemodynamic functioning in middle-aged adults. Psychosom Med. 1999;61:525-531.
118. Barnes VA, Treiber FA, Davis H. Impact of transcendental meditation on cardiovascular function at rest and during acute stress in adolescents with high normal blood pressure. J Psychosom Res. 2001;51:597-605.
119. Wenneberg SR, Schneider RH, Walton KG, Maclean CR, Levitsky DK, Salerno JW, Wallace RK, Mandarino JV, Rainforth MV, Waziri R. A controlled study of the effects of the transcendental meditation program on cardiovascular reactivity and ambulatory blood pressure. Int J Neurosci. 1997;89:15-28.
120. Sivasankaran S, Pollard-Quintner S, Sachdeva R, Pugeda J, Hoq SM, Zarich SW. The effect of a six-week program of yoga and meditation on brachial artery reactivity: do psychosocial interventions affect vascular tone? Clin Cardiol. 2006;29:393-398.
121. Phongsuphap S, Pongsupap Y, Chandanamattha P, Lursinsap C. Changes in heart rate variability during concentration meditation. Int J Cardiol. 2008;130:481-484.
122. Wu SD, Lo PC. Inward-attention meditation increases parasympathetic activity: a study based on heart rate variability. Biomed Res. 2008;29: 245-250.
123. Kiecolt-Glaser JK, Christian L, Preston H, Houts CR, Malarkey WB, Emery CF, Glaser R. Stress, inflammation, and yoga practice. Psychosom Med. 2010;72:113-121.
124. De Jong MJ, Moser DK, An K, Chung ML. Anxiety is not manifested by elevated heart rate and blood pressure in acutely ill cardiac patients. Eur J Cardiovasc Nurs. 2004;3:247-253.
125. Yeh GY, Wayne PM, Phillips RS. T'ai chi exercise in patients with chronic heart failure. Med Sport Sci. 2008;52:195-208.
126. Yeh GY, Wood MJ, Lorell BH, Stevenson LW, Eisenberg DM, Wayne PM, Goldberger AL, Davis RB, Phillips RS. Effects of tai chi mind-body movement therapy on functional status and exercise capacity in patients with chronic heart failure: a randomized controlled trial. Am J Med. 2004;117:541-548.
127. Curiati JA, Bocchi E, Freire JO, Arantes AC, Braga M, Garcia Y, Guimaraes G, Fo WJ. Meditation reduces sympathetic activation and improves the quality of life in elderly patients with optimally treated heart failure: a prospective randomized study. J Altern Complement Med. 2005;11:465-472.
128. Kostis JB, Rosen RC, Cosgrove NM, Shindler DM, Wilson AC. Nonpharmacologic therapy improves functional and emotional status in congestive heart failure. Chest. 1999;106:996-1001.
129. Klaus L, Beniaminovitz A, Choi L, Greenfield F, Whitworth GC, Oz MC, Mancini DM. Pilot study of guided imagery use in patients with severe heart failure. Am J Cardiol. 2000;86:101-104.
130. Yu DS, Lee DT, Woo J. Effects of relaxation therapy on psychologic distress and symptom status in older Chinese patients with heart failure. J Psychosom Res. 2007;62:427-437.
131. Chang BH, Hendricks A, Zhao Y, Rothendler JA, LoCastro JS, Slawsky MT. A relaxation response randomized trial on patients with chronic heart failure. J Cardiopulm Rehabil. 2005;25:149-157.
132. Luskin F, Reitz M, Newell K, Quinn TG, Haskell W. A controlled pilot study of stress management training of elderly patients with congestive heart failure. Prev Cardiol. 2002;5:168-172.
133. Pischke CR, Weidner G, Elliott-Eller M, Ornish D. Lifestyle changes and clinical profile in coronary heart disease patients with an ejection fraction of 40% in the multicenter lifestyle demonstration project. Eur J Heart Fail. 2007;9:928-934.
134. Sullivan MJ, Wood L, Terry J, Brantley J, Charles A, McGee V, Johnson D, Krucoff MW, Rosenberg B, Bosworth HB, Adams K, Cuffe MS. The support, education, and research in chronic heart failure study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure. Am Heart J. 2009;157:84-90.
135. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol. 2005;45:637-651.
136. Aquilante CL, Terra SG, Schofield RS, Pauly DF, Hatton PS, Binkley PF, Johnson JA. Sustained restoration of autonomic balance with longbut not short-acting metoprolol in patients with heart failure. J Card Fail. 2006;12:171-176.
137. Panina G, Khot UN, Nunziata E, Cody RJ, Binkley PF. Role of spectral measures of heart rate variability as markers of disease progression in patients with chronic congestive heart failure not treated with angiotensin-converting enzyme inhibitors. Am Heart J. 1996;131:153-157.
138. Panina G, Khot UN, Nunziata E, Cody RJ, Binkley PF. Assessment of autonomic tone over a 24-hour period in patients with congestive heart failure: relation between mean heart rate and measures of heart rate variability. Am Heart J. 1995;129:748-753.
139. Binkley PF, Nunziata E, Cody RJ. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration. Am Heart J. 1994;128:1147-1156. (Pubitemid 124007046)
140. Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol. 2006;98:673-680.
141. Haynes PL. The role of behavioral sleep medicine in the assessment and treatment of sleep disordered breathing. Clin Psychol Rev. 2005;25: 673-705.
142. Jiang W, O'Connor C, Silva SG, Kuchibhatla M, Cuffe MS, Callwood DD, Zakhary B, Henke E, Arias RM, Krishnan R, SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebocontrolled trial of sertraline for major depression with congestive heart failure. Am Heart J. 2008;156:437-444.
143. O'Connor CM. Safety and efficacy of sertraline for depression in patients with congestive heart failure (SADHART-CHF; Abstract). Heart Failure Society of American 2008 scientific meeting: September 22, 2008; Toronto, Ontario. Late-Breaking Clinical Trials 1.
144. Bozzini S, Gambelli P, Boiocchi C, Schirinzi S, Falcone R, Buzzi P, Storti C, Falcone C. Coronary artery disease and depression: possible role of brain-derived neurotrophic factor and serotonin transporter gene polymorphisms. Int J Mol Med. 2009;2:813-818.
145. Ornish D, Lin J, Daubenmier J, Weidner G, Epel E, Kemp C, Magbanua MJ, Marlin R, Yglecias L, Carroll PR, Blackburn EH. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol. 2008;9:1048-1057.